Medication De-escalation in Type 2 Diabetes: A Review of Evidence-Based Strategies for Combination Therapy Reduction

This narrative review summarizes evidence on the topic of de-escalation of medications in patients with Type 2 Diabetes (T2D) who achieve glycemic control on combination therapy. The study reviews evidence from available clinical studies, expert opinions, and observations to assess the strategies, risks, and outcomes of de-escalating antidiabetic therapy in patients with T2D who have met their glycemic goals. It concludes that once the targets are achieved, continuing with complicated medication regimes can be even more risky without any benefit. Once glucose is controlled, the stepwise de-intensification of regimens may reduce polypharmacy and hypoglycemia. The evidence supports decreasing or discontinuing the use of insulin and sulfonylureas first because they are associated with the highest risk of hypoglycemia. Insulin remains the site of de-escalation. Sequential withdrawal is demonstrated to be safer than discontinuation of medications concurrently, with discontinuation of high-risk medications ranked first. SGLT2 inhibitors and GLP-1 receptor agonists have cardiovascular and renal protective effects, and therefore, it is important to consider their withdrawal. DPP-4 inhibitors may be among the safest agents to discontinue from a glycemic standpoint, given their glucose-dependent mechanism of action and low risk of hypoglycemia, while metformin should remain the mainstay of therapy. Medication de-escalation is more likely to be successful in patients who have been diabetic for a shorter period, have a lower baseline HbA1c, have fewer complications, and are committed to healthy lifestyle choices. Older people and patients with comorbidities need a more individualized approach and the chance to contribute to decision-making. As there are limited high-quality trials to define best practices for de-escalation, structured monitoring, and clear criteria for re-escalation are required. In addition, any benefits of de-escalation must be weighed against the risks of withdrawing agents that provide cardiovascular or renal protection. Medication de-escalation seems feasible in patients who are motivated and have good glycemic control, and this is associated with a decreased treatment burden and lower risks. Nevertheless, additional quality trials are required to inform and normalize the pathways of de-intensification.